Clinical Data Novartis reveals more data behind Pluvicto expansion bid PharmaphorumNovartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaphorum Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer. Oncology Read full story Post navigation Previous: Regeneron immunotherapy combo comes up short in melanoma trialNext: AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
